Literature DB >> 19898978

Three familial cases of drug-resistant Mycoplasma pneumoniae infection.

Shintaro Kamizono1, Hitomi Ohya, Sadanobu Higuchi, Norio Okazaki, Mitsuo Narita.   

Abstract

UNLABELLED: Mycoplasma pneumoniae infection is believed to result from defective host immune response rather than from direct cell injury by the organism itself. In this context, emergence of drug-resistant M. pneumoniae may provide us with special opportunities to study the pathogenesis from a clinical point of view. In this report, three patients with intrafamilial M. pneumoniae infection are presented. M. pneumoniae was isolated with a Hayflick pleuropneumonia-like organism diphasic medium. Minimal inhibitory concentrations of antibiotics were determined by a broth microdilution method. Polymerase chain reaction and restriction fragment length polymorphism analysis were done to determine point mutation in domain V of the 23S rRNA gene. As a result, all three strains from the three intrafamilial cases had the same drug-resistant point mutation, specifically A-to-G transition at position 2063. However, their clinical courses were quite different; a 6-year-old girl suffered severe pneumonia, a 5-year-old girl had mild pneumonia, and a 3-year-old boy had only a fever of 1-day duration without pneumonia.
CONCLUSIONS: Our clinical and laboratory observations strongly support the idea that the host immune maturity, rather than a virulence factor of the organism, is a major determinant factor of disease severity of M. pneumoniae infection and that drug resistance does not necessarily lead to a serious clinical outcome.

Entities:  

Mesh:

Year:  2009        PMID: 19898978     DOI: 10.1007/s00431-009-1100-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  28 in total

1.  Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro.

Authors:  N Okazaki; M Narita; S Yamada; K Izumikawa; M Umetsu; T Kenri; Y Sasaki; Y Arakawa; T Sasaki
Journal:  Microbiol Immunol       Date:  2001       Impact factor: 1.955

2.  Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation.

Authors:  Miyuki Morozumi; Keiko Hasegawa; Reiko Kobayashi; Nagako Inoue; Satoshi Iwata; Haruo Kuroki; Naohisa Kawamura; Eiichi Nakayama; Takeshi Tajima; Kouichi Shimizu; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

3.  Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.

Authors:  Miyuki Morozumi; Satoshi Iwata; Keiko Hasegawa; Naoko Chiba; Reiko Takayanagi; Keita Matsubara; Eiichi Nakayama; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

Review 4.  Mechanisms of drug resistance in Mycoplasma pneumoniae.

Authors:  C M Bébéar; S Pereyre
Journal:  Curr Drug Targets Infect Disord       Date:  2005-09

5.  In vitro development of resistance to erythromycin, other macrolide antibiotics, and lincomycin in Mycoplasma pneumoniae.

Authors:  Y Nitu; S Hasegawa; H Kubota
Journal:  Antimicrob Agents Chemother       Date:  1974-05       Impact factor: 5.191

6.  In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.

Authors:  I A Critchley; M E Jones; P D Heinze; D Hubbard; H D Engler; A T Evangelista; C Thornsberry; J A Karlowsky; D F Sahm
Journal:  Clin Microbiol Infect       Date:  2002-04       Impact factor: 8.067

7.  Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients.

Authors:  M Ieven; D Ursi; H Van Bever; W Quint; H G Niesters; H Goossens
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

8.  Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis.

Authors:  O Peuchant; A Ménard; H Renaudin; M Morozumi; K Ubukata; C M Bébéar; S Pereyre
Journal:  J Antimicrob Chemother       Date:  2009-05-09       Impact factor: 5.790

9.  Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae.

Authors:  T S Lucier; K Heitzman; S K Liu; P C Hu
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

10.  Isolation of Mycoplasma pneumoniae from children with lower-respiratory-tract infections.

Authors:  Y Nagayama; N Sakurai; K Yamamoto; A Honda; M Makuta; R Suzuki
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

View more
  3 in total

1.  Epidemiological characteristics and meteorological factors of childhood Mycoplasma pneumoniae pneumonia in Hangzhou.

Authors:  Ying-Chun Xu; Lan-Juan Zhu; Dan Xu; Xiao-Fen Tao; Shu-Xian Li; Lan-Fang Tang; Zhi-Min Chen
Journal:  World J Pediatr       Date:  2011-08-07       Impact factor: 2.764

2.  Detection of Mycoplasma pneumoniae in different respiratory specimens.

Authors:  Dan Xu; Shuxian Li; Zhimin Chen; Lizhong Du
Journal:  Eur J Pediatr       Date:  2010-11-24       Impact factor: 3.183

3.  Cluster of macrolide-resistant Mycoplasma pneumoniae infections in Illinois in 2012.

Authors:  Victoria Tsai; Bernard B Pritzker; Maureen H Diaz; Jonas M Winchell; Lauri A Hicks; Brianna Petrone; Alvaro Benitez; Bernard J Wolff; Kenneth L Soyemi
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.